Novo Nordisk will begin a new late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10, according to a entry.

A popular diabetes drug just got a major new approval -- and it could be a game-changer for millions of Americans a ...

In an important regulatory win for Denmark’s Novo Nordisk, the US Food and Drug Administration (FDA) yesterday approved ...

A multi-million dollar Super Bowl ad from telehealth company Hims and Hers downplays risks and side effects of compounded ...

Type 2 diabetes is a leading cause of chronic kidney disease, which affects more than 1 in 7 U.S. adults. The new approval ...

Telehealth company Hims & Hers is playing offense in a new commercial slated to air during the Super Bowl next month. | Telehealth company Hims & Hers is playing offense in a new commercial slated to ...

Health-care companies slipped, as traders rotated back into sectors more associated with artificial-intelligence developments. Novo Nordisk said the Food and Drug Administration approved the ...

Chronic kidney disease affects about 37 million adults in the United States and is expected to rise. It is a common ...

Hims & Hers, a tele-health start-up, aims to stand apart from dozens of Super Bowl commercials hawking snacks with a spot ...

Telehealth provider will make its big game debut as the semaglutide shortage continues to sustain the firm’s lower-priced ...

Minnesota Attorney General Keith Ellison says his office has reached a settlement with Novo Nordisk over high insulin ...